Designing a broad-spectrum integrative approach for cancer prevention and treatment

Abstract

Targeted therapies and the consequent adoption of “personalized” oncology have achieved notable successes in some cancers; however, significant problems remain with this approach. Many targeted therapies are highly toxic, costs are extremely high, and most patients experience relapse after a few disease-free months. Relapses arise from genetic heterogeneity in tumors, which harbor therapy-resistant immortalized cells that have adopted alternate and compensatory pathways (i.e., pathways that are not reliant upon the same mechanisms as those which have been targeted). To address these limitations, an international task force of 180 scientists was assembled to explore the concept of a low-toxicity “broad-spectrum” therapeutic approach that could simultaneously target many key pathways and mechanisms. Using cancer hallmark phenotypes and the tumor microenvironment to account for the various aspects of relevant cancer biology, interdisciplinary teams reviewed each hallmark area and nominated a wide range of high-priority targets (74 in total) that could be modified to improve patient outcomes. For these targets, corresponding low-toxicity therapeutic approaches were then suggested; many of which were phytochemicals. Proposed actions on each target and all of the approaches were further reviewed for known effects on other hallmark areas and the tumor microenvironment. Potential contrary or procarcinogenic effects were found for 3.9% of the relationships between targets and hallmarks, and mixed evidence of complementary and contrary relationships was found for 7.1%. Approximately 67% of the relationships revealed potentially complementary effects, and the remainder had no known relationship. Among the approaches, 1.1% had contrary, 2.8% had mixed and 62.1% had complementary relationships. These results suggest that a broad-spectrum approach should be feasible from a safety standpoint. This novel approach has potential to help us address disease relapse, which is a substantial and longstanding problem, so a proposed agenda for future research is offered.

Emodin induces hepatocellular carcinoma cell apoptosis through MAPK and PI3K/AKT signaling pathways in vitro and in vivo

“…Many agents extracted from natural plants have shown their effects in the prevention and treatment of cancer (4). Among these, many of the medicines derive from Traditional Chinese Medicine (TCM) and have been confirmed to be effective in the treatment of a number of tumors via targeting and regulating multiple molecular pathways (5,6).…”

Dietary Supplements that Works - Verify then trust

“…In other words -verify then trust! Opinion "The Halifax Project" international group recently summarized a comprehensive approach to cancer prevention and treatment by targeting many specific, high priority anti-cancer mechanisms and pathways [1]. Although targeted therapies are principally effective, they are also highly toxic, expensive, and prone to relapses.…”

Redefining advances in modern oncology research

“…To tackle the high toxicity and extremely high cost associated with current targeted therapies, an international task force of 350 scientists from 31 countries has launched the "Halifax Project". The aim of this project is to explore the concept of a "broadspectrum" prophylactic and therapeutic approach of using low-cost and low-toxicity chemicals from plants or foods that could simultaneously target many key pathways and mechanisms [24] .…”